Executive Director, US Controller (FP&A) bei Menarini Group

Executive Director of Financial Planning & Analysis (FPA) (US Controller)

Opportunity

The Executive Director, FPA (US Controller) is a key financial leader of Menarini Stemline US organization and a key financial partner to the US leadership. The position holder will lead the US team and the financial planning processes, monthly reporting of financial metrics and insightful analysis to gauge business performance and resource allocation that aligns with organizational priorities.

Position reports in dotted line to the Oncology Global Head of FP&A (Global Controller) and direct line to the US Chief Accounting and Financial Officer.

*Please note that this is a hybrid role and a weekly onsite presence is required in Stemline's NYC offices.

Responsibilities

•  Leads financial planning activities such as the annual budget, reforecasts and strategic plan for the US Affiliate.
• Leads monthly financial performance reporting, working in close cooperation with the US accounting and procurement team.
• Leads the preparation of financials materials to support US Board Meetings presentations.
• Quantifies financial risks and opportunities for top and bottom line against budget.
• Reports on key metrics for financial performance measurement and forecasting accuracy for the full US P&L.
• Ensures that financial planning submissions comply with Menarini financial reporting requirements
• Works in partnership with the Global Oncology leadership and the US Affiliate leadership to ensure attainment of performance goals.
• Reinforces financial planning and reporting timelines, policies and procedures with assigned functions
• Recommends financial system applications to improve financial planning and reporting efficiencies
• Cash flow forecasting
• Intercompany royalty and R&D recharge calculations with affiliates
• Guides FPA Team on the use of the planning system to achieve expected utilization levels and assure its successful adoption
• Performs ad-hoc analyses and presents findings to finance and business leadership
• Participates with internal cross-functional teams on ad hoc financial and operational projects as assigned

Responsibilities

• Leads financial planning activities such as the annual budget, reforecasts and strategic plan for the US Affiliate.
• Leads monthly financial performance reporting, working in close cooperation with the US accounting and procurement team.
• Leads the preparation of financials materials to support US Board Meetings presentations.
• Quantifies financial risks and opportunities for top and bottom line against budget.
• Reports on key metrics for financial performance measurement and forecasting accuracy for the full US P&L.
• Ensures that financial planning submissions comply with Menarini financial reporting requirements
• Works in partnership with the Global Oncology leadership and the US Affiliate leadership to ensure attainment of performance goals.
• Reinforces financial planning and reporting timelines, policies and procedures with assigned functions
• Recommends financial system applications to improve financial planning and reporting efficiencies
• Cash flow forecasting
• Intercompany royalty and R&D recharge calculations with affiliates
• Guides FPA Team on the use of the planning system to achieve expected utilization levels and assure its successful adoption
• Performs ad-hoc analyses and presents findings to finance and business leadership
• Participates with internal cross-functional teams on ad hoc financial and operational projects as assigned

• Bachelor’s degree in Finance, Accounting, or related field required.
• 15+ years of progressive experience in financial planning and analysis
• FPA experience in growing Biotech companies is required.
• Previous Big Pharma experience is a plus.
• Ability to work and perform in fast-paced, dynamic and ambitious growing Biotech organization.
• Experience in Commercial FPA is required, with a strong understanding of US pharma/biotech industry (such as gross to net sales forecasting, reporting, etc).
• Experience in R&D FPA a plus.
• SAP experience a plus.
• Highly collaborative with the ability to navigate compexities amongst global finance and cross-functional peers.
• Hands-on leader, capable of leading by example, with proven ability to build, develop and coach a high-performing US FPA team.
• Capable of dealing with pressure and tight deadlines.
• Strong work ethic to ensure financial and HR compliance.

Please note--this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.

Base Salary Range of $245,000-$325,000.  Menarini Stemline offers generous compensation and benefits packages including Fidelity 401(k) (with company match), PPO and HDHP insurance plans, company-paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees.  All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.